Xin Lang Cai Jing·2025-11-18 07:09Group 1 - The core viewpoint of the articles highlights the recent decline in the stock price of Spring Medical, which has dropped 1.56% to 25.95 CNY per share, with a total market value of 9.954 billion CNY and a cumulative decline of 7.32% over the past four days [1] - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants, exporting to various regions including Asia, South America, Africa, Oceania, and Europe [1] - The company's revenue composition is heavily reliant on medical device products, accounting for 99.89% of total revenue, with only 0.11% from other sources [1] Group 2 - According to data, the Fuyong Fund has a significant holding in Spring Medical, with its Fuyong Research Optimal Mixed A Fund holding 64,400 shares, representing 1.8% of the fund's net value, and it ranks as the sixth-largest holding [2] - The Fuyong Research Optimal Mixed A Fund has experienced a year-to-date return of 47.67%, ranking 1019 out of 8140 in its category, and a one-year return of 45.61%, ranking 1043 out of 8057 [2] - The fund manager, Lang Chengcheng, has been in position for 5 years and 127 days, with the fund's total asset size at 1.242 billion CNY, achieving a best return of 61.86% and a worst return of -18.92% during his tenure [3]